Comparison
Modafinil vs Atomoxetine (Strattera)
Modafinil
A eugeroic — a wakefulness-promoting compound — originally developed for narcolepsy. The most-studied prescription cognitive enhancer outside of ADHD treatment. Produces 12–15 hour windows of sustained alertness without the euphoria, abuse potential, or cardiovascular load of amphetamines. Prescription-only in nearly every jurisdiction.
Atomoxetine (Strattera)
Prescription non-stimulant ADHD medication. Selective norepinephrine reuptake inhibitor. No abuse potential.
| Field | Modafinil | Atomoxetine (Strattera) |
|---|---|---|
| Category | stimulant | stimulant |
| Dose range | 100–200mg | 40–100mg |
| Half-life | 14h | 5h |
| Onset | 45min | 60min |
| Evidence | EVIDENCEA | EVIDENCEA |
| Safety | ●●●○○ | ●●●●○ |
| Legal (US) | USSchedule IV | USRx |
| PubMed refs | 3200 | 3800 |
The comparison in plain English
Auto-generated from dataModafinil and Atomoxetine (Strattera) are both in the stimulant category respectively. Modafinil A eugeroic — a wakefulness-promoting compound — originally developed for narcolepsy. Atomoxetine (Strattera) Prescription non-stimulant ADHD medication.
Bottom line
Modafinil (evidence A, safety 3/5) matches the evidence base of Atomoxetine (Strattera) (evidence A, safety 4/5). Atomoxetine (Strattera) has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose Modafinil if
Modafinil is the better fit when your goal aligns with its mechanism (Inhibits dopamine reuptake via the dopamine transporter (DAT), increasing extracellular dopamine in the prefrontal cortex) and the dose range (100–200mg) suits your protocol. Half-life is 14h.
Choose Atomoxetine (Strattera) if
Atomoxetine (Strattera) is the better fit when your goal aligns with its mechanism (Selective norepinephrine reuptake inhibitor (NRI) — blocks the norepinephrine transporter, increasing extracellular norepinephrine) and the dose range (40–100mg) suits your protocol. Half-life is 5h.